Navion Neurosciences has filed a notice of an exempt offering of securities to raise $5,099,999.00 in New Funding.
According to filings with the U.S. Securities and Exchange Commission, Navion Neurosciences is raising up to $5,099,999.00 in new funding. The federal securities law requires the notice to be filed...
According to filings with the U.S. Securities and Exchange Commission, Navion Neurosciences is raising up to $5,099,999.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About Navion Neurosciences
At Navion Neurosciences, we exist to solve problems for people living with conditions driven by abnormal neuronal firing, including uncontrolled seizures and chronic pain. Through AI/ML enhanced chemistry, precision science and deep understanding of the nervous system, we are developing a new generation of medicines designed to restore control, improve daily life and bring hope to families. We are pioneering precision sodium channel therapeutics to address debilitating neurological conditions starting with genetic epilepsies and chronic neuropathic pain. We aim to deliver meaningful, lasting impact where current treatments fall short.
To learn more, visit https://navionneuro.com/
LinkedIn: https://www.linkedin.com/company/navion-neurosciences-inc/
Contact:
Andrew Krouse, Chief Executive Officer
https://www.linkedin.com/in/andrew-krouse-64546b7/
SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.
No Comment! Be the first one.